SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported):  June 14, 2016 (June 09, 2016)


CHEMBIO DIAGNOSTICS, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
 
0-30379
 
88-0425691
(State or other jurisdiction
 
(Commission File Number)
 
(IRS Employer
of Incorporation)
     
Identification Number)
   
3661 Horseblock Road
   
   
Medford, NY 11763
   
   
(Address of principal executive offices)
   
   
631-924-1135
   
   
(Registrant's Telephone Number)
   
 
N/A
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 
 
 


Item 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

At the Company's annual stockholder meeting on June 9, 2016, stockholders elected the directors of the Company named below to serve until the next annual meeting of stockholders or until their respective successors are elected and qualified.  Stockholders also ratified the selection of BDO USA LLP as the Company's independent registered certified accountants to audit the Company's financial statements as of and for the year ending December 31, 2016, and approved, on an advisory basis, the compensation paid to the Company's named executive officers.  A tabulation of the matters voted on at this annual stockholder meeting is set forth below.
 

Proposal #1:– Election of Directors
 
Kathy L. Davis
   
Peter Kissinger
 
Dr. Gary Meller
 
John J. Sperzel III
For
 
 3,257,154
   
3,269,128
 
3,270,128
 
3,519.953
Withheld/Against
 
463,854
   
451,880
 
450,880
 
201,055
Broker non-votes
 
4,615,141
   
4,615,141
 
4,615,141
 
4,615,141

Proposal
 
Ratifying BDO USA LLP as the Company's Independent Auditors for the year ending December 31, 2016
 
Approve Compensation  paid to the Company's named Executive Officers
   
 
 Vote to Adjourn Or Postpone the meeting
 
Vote on Other Business
For
 
8,222,264
 
3,320,533
     
7,454,054
 
5,982,727
Withheld/Against
 
110,510
 
138,417
     
867,236
 
2,083,100
Abstain
 
3,375
 
262,058
     
13,804
 
269,266
Broker non-votes
 
---
 
4,615,141
     
---
 
---

 


 
 
 
 
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date:  June 14, 2016                                                                                        Chembio Diagnostics, Inc.



By:    /s/ John J. Sperzel, III                                      
John J. Sperzel III
Chief Executive Officer